Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LFCRCHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.
Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights
LFCRNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders. If you currently own Lifecore stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference
LFCR(NASDAQ:LFCR) CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 24th Annual Contract Pharma Contracting and Outsourcing Conference. Recognized as one of the top annual events for pharmaceutical outsourcing and contract manufacturing, the Contract Pharma conference will take place September 18-19, 2025, in New Brunswick, NJ.
Lifecore Biomedical to Participate in Upcoming Investor Conferences
LFCR(NASDAQ:LFCR) CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences. Details regarding Lifecore’s participation are as follows:
Lifecore Biomedical Receives Early $10M Payout From Filler Sale, Boosting Balance Sheet And Supporting $300M Revenue Capacity Strategy
LFCRWilliam Blair Initiates Coverage On Lifecore Biomedical with Outperform Rating
LFCRLifecore Biomedical Reiterates FY25 Revenue ~$126.5M-$130M Vs $128.439M Est.
LFCRLifecore Biomedical Q3 2025 GAAP EPS $(0.47) Misses $(0.15) Estimate, Sales $35.154M Beat $33.229M Estimate
LFCRLifecore Biomedical Says Humanetics Selected Company To Provide Range Of CDMO Services To Support Continued Development Of BIO 300 For Prevention Of Acute Radiation Syndrome
LFCR